JNJ
New data, same old symptom: inflammation
Johnson & Johnson rolled out late-breaking Phase 2b data on JNJ-4804, a fixed-dose co-antibody aimed at the IL-23 and TNF pathways — basically, the immune system’s overachieving troublemakers in inflammatory bowel disease. In the DUET-UC and DUET-CD studies, the drug posted the highest clinical and endoscopic outcomes versus golimumab and guselkumab in a stubborn patient group that had already failed two or more systemic therapy classes.
Why investors should care
This isn’t just science fair bragging rights. Refractory ulcerative colitis and Crohn’s disease are exactly the kind of markets where a better therapy can win meaningful share, especially if it can show durable benefit and a clean enough profile to keep doctors interested. J&J is also signaling confidence here by saying the data support moving into Phase 3 — pharma-speak for “we think this thing might be real.”
The bigger J&J picture
The company presented the results at Digestive Disease Week 2026, alongside a pile of other sponsored abstracts, which tells you J&J is still using its giant research machine to feed the pipeline. Investors don’t buy shares for conference posters alone, of course, but stronger clinical evidence in IBD helps de-risk the asset and gives the Street one more reason to treat J&J like a steady pipeline-plus-dividend machine instead of just a sleepy mega-cap.
Big picture: if JNJ-4804 keeps this momentum in Phase 3, J&J could be looking at another meaningful immune-disease franchise — and those are the kinds of assets Wall Street happily pays up for.